MedTrace Logo

Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention

NCT03476369 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-02-04

Study results available
· View outcomes & findings →

Summary

During a percutaneous coronary intervention (PCI), Fentanyl is commonly used for sedation. Ticagrelor is also routinely used as anti-platelet agent during PCI. However, a recent study has demonstrated the decrease in effectiveness of Ticagrelor when administered along with Fentanyl. Hence this study was designed to further assess the interaction between crushed vs non crushed Ticagrelor and Fentanyl given during PCI procedures.

Conditions

  • Percutaneous Coronary Intervention

Interventions

DRUG

Fentanyl

Premedicated with Fentanyl (at least 25mcg by IV)

DRUG

Ticagrelor 90Mg Tablet

Ticagrelor administered crushed vs non-crushed

Sponsors & Collaborators

  • The Guthrie Clinic

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-18
Primary Completion
2025-01-23
Completion
2025-01-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03476369 on ClinicalTrials.gov